COVID-19 associated brainstem encephalitis - is SARS-CoV-2 a neurotropic agent?
Recruiting
- Conditions
- COVID-19U07.1COVID-19, virus identified
- Registration Number
- DRKS00021439
- Lead Sponsor
- Klinik für Neurologie und Neurophysiologie Universitätsklinikum Freiburg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Age > 18 Years
Proof of SARS-CoV-2 Infection
Anamnestic Anosmia/Ageusia
Clinical or radiological indication of encephalitis in COVID-19 disease
Exclusion Criteria
Lack of possibility for oral and written patient information
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Predictive value of the clinical symptoms ageusia and anosmia for a negative outcome of COVID-19 disease and for the detection of changes in the brain, meninges and cerebrospinal fluid in the instrumental diagnostics.
- Secondary Outcome Measures
Name Time Method • Correlation between the results of different diagnostic procedures and the clinical course<br>• Correlation between the results of various diagnostic procedures and vital parameters and, if applicable, ventilation parameters and clinical findings<br>• Death from COVID-19 disease<br>• Further research questions are derived in the course of the project